Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 1

Cannabinoids in the management of difficult to treat pain

Authors Ethan B Russo

Published Date May 2008 Volume 2008:4(1) Pages 245—259

DOI http://dx.doi.org/10.2147/TCRM.S1928

Published 13 May 2008

Ethan B Russo

GW Pharmaceuticals, Vashon, WA, USA

Abstract: This article reviews recent research on cannabinoid analgesia via the endocannabinoid system and non-receptor mechanisms, as well as randomized clinical trials employing cannabinoids in pain treatment. Tetrahydrocannabinol (THC, Marinol®) and nabilone (Cesamet®) are currently approved in the United States and other countries, but not for pain indications. Other synthetic cannabinoids, such as ajulemic acid, are in development. Crude herbal cannabis remains illegal in most jurisdictions but is also under investigation. Sativex®, a cannabis derived oromucosal spray containing equal proportions of THC (partial CB1 receptor agonist) and cannabidiol (CBD, a non-euphoriant, anti-inflammatory analgesic with CB1 receptor antagonist and endocannabinoid modulating effects) was approved in Canada in 2005 for treatment of central neuropathic pain in multiple sclerosis, and in 2007 for intractable cancer pain. Numerous randomized clinical trials have demonstrated safety and efficacy for Sativex in central and peripheral neuropathic pain, rheumatoid arthritis and cancer pain. An Investigational New Drug application to conduct advanced clinical trials for cancer pain was approved by the US FDA in January 2006. Cannabinoid analgesics have generally been well tolerated in clinical trials with acceptable adverse event profiles. Their adjunctive addition to the pharmacological armamentarium for treatment of pain shows great promise.

Keywords: cannabinoids, tetrahydrocannabinol, cannabidiol, analgesia, pain management, multiple sclerosis

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis [Corrigendum]

Frati F, Cecchi L, Scala E, Ridolo E, Dell'Albani I, Makrì E, Pajno GB, Incorvaia C

Biologics: Targets and Therapy 2015, 9:45-46

Published Date: 29 June 2015

Peak expiratory flow rate as a surrogate for forced expiratory volume in 1 second in COPD severity classification in Thailand

Pothirat C, Chaiwong W, Phetsuk N, Liwsrisakun C, Bumroongkit C, Deesomchok A, Theerakittikul T, Limsukon A

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1213-1218

Published Date: 25 June 2015

The role of perioperative oral nutritional supplementation in elderly patients after hip surgery

Liu M, Yang J, Yu X, Huang X, Vaidya S, Huang F, Xiang Z

Clinical Interventions in Aging 2015, 10:849-858

Published Date: 11 May 2015

Effects of different resistance training frequencies on flexibility in older women

Carneiro NH, Ribeiro AS, Nascimento MA, Gobbo LA, Schoenfeld BJ, Achour Júnior A, Gobbi S, Oliveira AR, Cyrino ES

Clinical Interventions in Aging 2015, 10:531-538

Published Date: 5 March 2015

Sustained-release nanoART formulation for the treatment of neuroAIDS

Jayant RD, Atluri VSR, Agudelo M, Sagar V, Kaushik A, Nair M

International Journal of Nanomedicine 2015, 10:1077-1093

Published Date: 4 February 2015

HCA519/TPX2: a potential T-cell tumor-associated antigen for human hepatocellular carcinoma

Aref AM, Hoa NT, Ge L, Agrawal A, Dacosta-Iyer M, Lambrecht N, Ouyang Y, Cornforth AN, Jadus MR

OncoTargets and Therapy 2014, 7:1061-1070

Published Date: 13 June 2014

Analyzing the behavior of a porous nano-hydroxyapatite/polyamide 66 (n-HA/PA66) composite for healing of bone defects

Xiong Y, Ren C, Zhang B, Yang H, Lang Y, Min L, Zhang W, Pei F, Yan Y, Li H, Mo A, Tu C, Duan H

International Journal of Nanomedicine 2014, 9:485-494

Published Date: 13 January 2014

Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials

Grossman E, Laudon M, Zisapel N

Vascular Health and Risk Management 2011, 7:577-584

Published Date: 15 September 2011

Cerebral blood flow response to flavanol-rich cocoa in healthy elderly humans

Farzaneh A Sorond, Lewis A Lipsitz, Norman K Hollenberg, Naomi DL Fisher

Neuropsychiatric Disease and Treatment 2008, 4:433-440

Published Date: 16 April 2008